AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.

Original reporting
Published Oct 27, 2026, 6:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 6:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AZN
Bearish
high confidence
Mentioned
$AZN · $IPHA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AZNBearishMed
01

Why it matters

The postponement removes a near‑term catalyst for both AstraZeneca and Innate Pharma, likely leading to short‑term price weakness while extending the timeline for potential revenue recognition.

02

Market read

The delay is a fresh, material development for two listed biotech/pharma companies, affecting near‑term price dynamics.

03

What to watch

The delay could allow additional safety data to be gathered, possibly improving eventual trial outcomes.

Relevance 7/10Novelty 7/10Timing: immediate, as the delay was just announced

Background

The PACIFIC-9 trial evaluates durvalumab combined with monalizumab or oleclumab for unresectable Stage III NSCLC. The trial enrollment is complete, and the readout was previously expected in H2 2026.

Company-level read

Ticker impact

$AZNBearishHigh confidence
Context

AstraZeneca postponed the PACIFIC-9 Phase 3 lung‑cancer trial readout to H1 2027, delaying expected data.

Expected impact

likely downward pressure as the market prices in the postponed readout

Evidence & confidence

Trial data is a key catalyst; pushing it back reduces near‑term upside and may trigger sell‑offs.

$IPHABearishHigh confidence
Context

Innate Pharma, co‑developer of monalizumab in the AstraZeneca‑led PACIFIC-9 trial, announced the data readout delay to H1 2027.

Expected impact

potential short‑term decline as investors reassess timing of commercial upside

Evidence & confidence

The delay directly affects Innate Pharma’s expected milestone and revenue timeline.

Market effects

May dampen sentiment in the oncology biotech sector as a key trial timeline is pushed back.

European biotech markets could see modest pressure due to the delay affecting a French‑listed company.

Limited to investors tracking AstraZeneca and related oncology partners.

Counterpoint

Some investors may view the delay as a sign of rigorous data collection, potentially supporting a longer‑term bullish stance.

Key entities

  • AstraZeneca

    Lead sponsor of the PACIFIC-9 trial, large multinational pharma.

  • Innate Pharma

    Developer of monalizumab, partner in the trial.

Related articles

$IPHAHighAI 8/10

Why is Innate Pharma stock sliding today?

Innate Pharma (IPH) shares fell 21.1% to $1.05 after presenting Phase 1 clinical data for IPH4502. The drug showed a 33% response rate in non-urothelial tumors but modest results in urothelial cancer, its primary target. BTIG had a $9.00 price target, but the data underwhelmed, leading to a 52-week low of $1.01. The broader market decline also contributed to the sell-off.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.